Recommendation of the President – Remsima (infliximab)

On 28 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 25/2025 on the appraisal of Remsima (infliximab) as part of the B.36 drug program “Treatment of patients with active ankylosing spondylitis (AS) (ICD-10: M45)”

Publication in Public Information Bulletin (BIP) >>